Mark Curtis
Mark is a Business Development Analyst at the Centre for Commercialization of Regenerative Medicine (CCRM), where he collaborates with the team to help evaluate the commercial potential of regenerative medicine and cell therapy technologies. He began his career at Princess Margaret Hospital studying cellular reprogramming of human skin cells. Following this project, he left the laboratory and took on a role with Bloom Burton & Co., a healthcare-focused investment dealer. While there he supported the advisory team in carrying out scientific diligence on early-stage biotechnology companies. Prior to joining CCRM he was a consultant to Stem Cell Therapeutics, a Toronto-based biotechnology company focused on developing therapeutics targeting cancer stem cells. Mark received a Master’s degree from the University of New South Wales in Sydney, where he studied the directed differentiation of embryonic stem cells, and a Bachelor’s degree in Biology, from Queen’s University. Follow Mark on Twitter @markallencurtis
Posts by: Mark
Cell Therapy Deal Review: February
Welcome to your deal review for the month of February. Astellas tied-off its acquisition of Ocata while GSK and Adaptimmune expanded their collaboration to develop cell-based immunotherapies. AVROBIO, a new cell and gene company based in Boston, Mass, and Toronto, Ontario, launched with programs in leukemia in Fabry disease. After a drawn out process, Astellas […]
Update from the Clinic: January
Welcome to your update from the clinic for the month of January. It was a quiet month in the clinic. However, we did see some clearances for various clinical studies, including Fate’s ProTmune in GvHD and Pluristem’s PLX-R18 in hematopoietic recovery following bone marrow transplant. Pluristem (PSTM) continues to increase the breadth of applications for […]
Cell Therapy Deal Review: January
Welcome to your Cell Therapy Deal Review for the month of January. Things got off to a quick start with a number of cell-based immunotherapy companies announcing deals and research collaborations out of the gate, including a third acquisition by Juno. Juno Therapeutics (JUNO) brought further depth to its research & discovery platform through the […]
ISCT webinar: Reimbursement re-cap
For those of you that missed ISCT’s recent webinar on manufacturing, needle-to-needle logistics and reimbursement, below is a brief re-cap of the key points on the reimbursement section that I provided. The presentation, including audio, should be available free on the ISCT website shortly. Thanks again to ISCT for hosting and Invetech, a member of […]